Skip to main content
Pure Biologics S.A. logo

Pure Biologics S.A. — Investor Relations & Filings

Ticker · PUR ISIN · PLPRBLG00010 LEI · 2594002TXS19AUYHIF82 WAR Manufacturing
Open in API
Filings indexed 515 across all filing types
Latest filing 2023-08-04 Director's Dealing
Country PL Poland
Listing WAR PUR

About Pure Biologics S.A.

https://purebiologics.com/

Pure Biologics S.A. is a biopharmaceutical company engaged in the discovery and development of novel biological drugs and non-systemic therapies. The company leverages its expertise in antibody and aptamer technologies to create innovative treatments. Its therapeutic portfolio is primarily focused on immuno-oncology. A key aspect of its strategy is the development of original, non-generic and non-biosimilar, biological drug candidates.

Recent filings

Filing Released Lang Actions
Powiadomienie na podstawie art. 19 MAR_Romuald Harwas
Director's Dealing Classification · 100% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of transaction(s) referred to in Article 19(1) of the MAR Regulation). It details a transaction involving a member of management ('Wiceprezes Zarządu Spółki' - Vice President of the Management Board) regarding the subscription of securities ('Warranty subskrypcyjne imienne serii A'). Article 19 of MAR (Market Abuse Regulation) mandates disclosures for transactions conducted by persons discharging managerial responsibilities (PDMRs). This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors). Comparing with definitions: - DIRS (Director's Dealing): Report of personal share transactions by company directors and executives (insider trades). This is the most accurate fit. - POS (Transaction in Own Shares): This usually refers to the company buying back or selling its own shares (treasury stock), not individual director transactions. Therefore, the classification is DIRS.
2023-08-04 Polish
Powiadomienie o transakcjach wykonywanych przez osoby pełniące obowiązki zarządcze w Spółce - Content (PL)
Director's Dealing Classification · 95% confidence The document text is very short (612 characters) and explicitly states that the Management Board ('Zarząd') is informing about receiving notifications regarding the subscription of warrants by management persons ('osoby pełniące obowiązki zarządcze'). Crucially, it states: 'Treść otrzymanych powiadomień Spółka przekazuje w załączeniu do niniejszego raportu bieżącego' (The content of the received notifications is provided by the Company attached to this current report). This structure—a brief announcement referencing attached details—strongly suggests a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since the content specifically relates to transactions by management/insiders (warrant subscription by VPs), it is closely related to insider dealing (DIRS). However, the primary action described is the *reporting* of these transactions, not the transaction itself, and the document is a 'raport bieżący' (current report). Given the content involves management personnel and transactions, DIRS is a strong candidate, but the format (announcing attached content) points towards RPA or RNS. Since DIRS specifically covers 'Report of personal share transactions by company directors and executives (insider trades)', and this is a notification of management subscribing to warrants (a form of insider transaction), DIRS is the most specific fit, even if it's a brief announcement of the filing itself. If the content were the actual MAR disclosure form, DIRS would be certain. As it is a current report announcing the receipt of MAR disclosures concerning management, DIRS remains the most relevant category for the *subject matter* being reported, although RPA/RNS covers the *format* of the announcement. Given the context of MAR (Market Abuse Regulation) filings concerning management actions, DIRS is prioritized over the general RPA/RNS.
2023-08-04 Polish
Wstępne potwierdzenie skuteczności oraz bezpieczeństwa kandydata PBA-0405 w modelach in vivo i skierowanie projektu PB004 do dalszych etapów rozwoju - Content (PL)
Regulatory Filings Classification · 100% confidence The document discusses the decision by the Management Board of Pure Biologics S.A. to advance molecule PBA-0405 (Project PB004) into Phase 0 clinical trials for treating certain cancers. It details preclinical proof-of-concept, toxicology studies, and future regulatory steps (eIND application to the FDA). This content relates to the company's ongoing research and development pipeline, specifically concerning drug development milestones. This type of detailed update on R&D progress, especially concerning clinical trial advancement, fits best under 'Capital/Financing Update' (CAP) if it implies a need for funding or is a major strategic development, or potentially 'Regulatory Filings' (RNS) if it's a mandatory disclosure of a significant operational milestone. Given the focus on advancing a drug candidate to human trials, which is a critical strategic and often financing-related event, and the lack of a specific category for R&D pipeline updates, 'CAP' (Capital/Financing Update) is a strong candidate as these milestones often trigger financing rounds. However, since it is a specific operational update regarding a drug development stage, and not explicitly about raising capital or debt, 'RNS' (Regulatory Filings) serves as the most appropriate general disclosure category for significant, non-standard operational news in the Polish context (ESPI reports are regulatory disclosures). Given the options, and the nature of the announcement being a significant operational/scientific milestone disclosure, RNS is the safest general classification, although it is a very specific update. If the document were a formal presentation or a detailed management discussion, other codes might apply. Since it is a formal announcement of a development milestone, RNS is appropriate as a catch-all for significant regulatory disclosures not covered elsewhere.
2023-07-31 Polish
Objęcie warrantów subskrypcyjnych serii B przez ACRX - Content (PL)
Capital/Financing Update Classification · 95% confidence The document text, written in Polish, discusses the subscription of warrants (warrantów subskrypcyjnych) by an investor (ACRX Investments Limited) based on a prior investment agreement and a resolution from the General Shareholders' Meeting (Zwyczajnego Walnego Zgromadzenia). The core subject is the issuance of securities (warrants) tied to future share subscription, which directly relates to changes in the company's capital structure or fundraising activities. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV). Given the specific nature of warrant issuance, CAP is the most appropriate classification.
2023-06-26 Polish
Tekst jednolity Statutu Spółki Pure Biologics S.A.
Governance Information Classification · 98% confidence The document text provided is a 'Tekst jednolity Statutu Spółki Pure Biologics S.A.' which translates to 'Consolidated Text of the Articles of Association of Pure Biologics S.A.'. This document details the fundamental rules, purpose, capital structure, share types, and governance framework of the company. This content is characteristic of a company's foundational legal document, which is typically filed with regulatory bodies or maintained as a core corporate governance document. Among the provided options, 'Governance Information' (CGR) is the closest fit, as the Articles of Association define the company's internal rules and structure. It is not an Annual Report (10-K), an Earnings Release (ER), or a specific shareholder communication like a Proxy Statement (PSI) or AGM material (AGM-R). Since it is a formal, comprehensive document detailing corporate structure and rules, CGR is the most appropriate classification.
2023-06-20 Polish
Treść zmienionych podstanowień Statutu Spółki Pure Biologics S.A.
Capital/Financing Update Classification · 98% confidence The document text is in Polish and details amendments to the company's Statute (Statut) resulting from resolutions passed at the Ordinary General Meeting (Zwyczajne Walne Zgromadzenie) on May 25, 2023. Specifically, it discusses authorizing the Management Board to increase share capital (kapitał zakładowy) under a 'target capital' scheme (kapitał docelowy) and the issuance of subscription warrants (warrantów subskrypcyjnych). These actions directly relate to changes in the company's capital structure and financing activities, such as share issuance and warrant allocation, which are core components of a Capital/Financing Update. Although it references resolutions from a General Meeting, the content focuses on the resulting structural changes (amendments to the statute regarding capital increase and warrants) rather than the meeting minutes or voting results themselves. Therefore, 'Capital/Financing Update' (CAP) is the most appropriate classification.
2023-06-20 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.